Skip to main content
TipRanks
Go Ultimate75% OFF

Bioline Rx (BLRX) Stock Statistics & Valuation Metrics

3 Followers

Total Valuation

Bioline Rx has a market cap or net worth of ILA 29.87M. The enterprise value is ILA 33.16M.

Market Cap
ILA 29.87M
Enterprise Value
ILA 33.16M

Share Statistics

Bioline Rx has 2,986,929,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
2,986,929,700
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Bioline Rx’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -33.24%.

Return on Equity (ROE)
-0.07
Return on Assets (ROA)
-0.03
Return on Invested Capital (ROIC)
-33.24%
Return on Capital Employed (ROCE)
-0.39
Revenue Per Employee
58.06K
Profits Per Employee
-57.81K
Employee Count
22
Asset Turnover
0.03
Inventory Turnover
0.38

Valuation Ratios

The current PE Ratio of Bioline Rx is -1.00. Bioline Rx’s PEG ratio is 0.00.

PE Ratio
-1.00
PS Ratio
6.65
PB Ratio
0.61
Price to FCF
-0.85
Price to Operating Cash Flow
-0.76
PEG Ratio
0.00

Income Statement

In the last 12 months, Bioline Rx had revenue of 1.28M and earned -1.27M in profits. Earnings per share was -0.00.

Revenue
1.28M
Gross Profit
462.21K
Operating Income
-11.14M
Pretax Income
-2.19M
Net Income
-1.27M
EBITDA
-10.61M
Earnings Per Share (EPS)
-0.00

Cash Flow

In the last 12 months, operating cash flow was -10.94M and capital expenditures 7.16M, giving a free cash flow of -10.97M billion.

Operating Cash Flow
-10.94M
Free Cash Flow
-10.97M
Free Cash Flow per Share
-0.00

Dividends & Yields

Bioline Rx pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-117.90%
Earnings Yield
-96.86%

Stock Price Statistics

Beta
0.46
52-Week Price Change
-47.37%
50-Day Moving Average
1.20
200-Day Moving Average
1.41
Relative Strength Index (RSI)
35.69
Average Volume (3m)
3.61M

Important Dates

Bioline Rx upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 31, 2026
Next Earnings Date
Nov 18, 2026
Ex-Dividend Date
―

Financial Position

Bioline Rx as a current ratio of 1.95, with Debt / Equity ratio of 55.78%

Current Ratio
1.95
Quick Ratio
1.78
Debt to Market Cap
0.72
Net Debt to EBITDA
-0.65
Interest Coverage Ratio
-8.04

Taxes

In the past 12 months, Bioline Rx has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Bioline Rx EV to EBITDA ratio is -1.12, with an EV/FCF ratio of -1.15.

EV to Sales
9.06
EV to EBITDA
-1.12
EV to Free Cash Flow
-1.15
EV to Operating Cash Flow
-1.16

Balance Sheet

Bioline Rx has ILA 12.99M in cash and marketable securities with ILA 7.94M in debt, giving a net cash position of ILA 5.05M billion.

Cash & Marketable Securities
ILA 12.99M
Total Debt
ILA 7.94M
Net Cash
ILA 5.05M
Net Cash Per Share
ILA 0.00
Tangible Book Value Per Share
ILA 0.00

Margins

Gross margin is 69.98%, with operating margin of -876.78%, and net profit margin of -575.77%.

Gross Margin
69.98%
Operating Margin
-876.78%
Pretax Margin
-730.90%
Net Profit Margin
-575.77%
EBITDA Margin
-810.22%
EBIT Margin
-835.24%

Analyst Forecast

The average price target for Bioline Rx is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-93.07%
EPS Growth Forecast
62.25%

Scores

Smart Score
―
AI Score
48